Bristol Myers Squibb Gross Margin 2010-2022 | BMY
Current and historical gross margin for Bristol Myers Squibb (BMY) over the last 10 years. The current gross profit margin for Bristol Myers Squibb as of March 31, 2022 is %.
| Bristol Myers Squibb Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2022-03-31 |
$46.96B |
$37.39B |
79.62% |
| 2021-12-31 |
$46.39B |
$36.45B |
78.57% |
| 2021-09-30 |
$45.47B |
$34.97B |
76.92% |
| 2021-06-30 |
$44.38B |
$33.68B |
75.88% |
| 2021-03-31 |
$42.81B |
$31.86B |
74.42% |
| 2020-12-31 |
$42.52B |
$30.75B |
72.31% |
| 2020-09-30 |
$39.40B |
$28.04B |
71.18% |
| 2020-06-30 |
$34.86B |
$24.22B |
69.47% |
| 2020-03-31 |
$31.01B |
$21.09B |
68.02% |
| 2019-12-31 |
$26.15B |
$18.07B |
69.10% |
| 2019-09-30 |
$24.17B |
$16.98B |
70.23% |
| 2019-06-30 |
$23.86B |
$16.80B |
70.43% |
| 2019-03-31 |
$23.29B |
$16.58B |
71.20% |
| 2018-12-31 |
$22.56B |
$16.09B |
71.34% |
| 2018-09-30 |
$22.04B |
$15.58B |
70.69% |
| 2018-06-30 |
$21.60B |
$15.21B |
70.42% |
| 2018-03-31 |
$21.04B |
$14.71B |
69.90% |
| 2017-12-31 |
$20.78B |
$14.76B |
71.05% |
| 2017-09-30 |
$20.57B |
$14.75B |
71.71% |
| 2017-06-30 |
$20.24B |
$14.69B |
72.60% |
| 2017-03-31 |
$19.97B |
$14.78B |
74.04% |
| 2016-12-31 |
$19.43B |
$14.46B |
74.42% |
| 2016-09-30 |
$18.47B |
$13.96B |
75.56% |
| 2016-06-30 |
$17.62B |
$13.31B |
75.55% |
| 2016-03-31 |
$16.91B |
$12.80B |
75.67% |
| 2015-12-31 |
$16.56B |
$12.65B |
76.39% |
| 2015-09-30 |
$16.53B |
$12.61B |
76.27% |
| 2015-06-30 |
$16.38B |
$12.55B |
76.60% |
| 2015-03-31 |
$16.11B |
$12.30B |
76.34% |
| 2014-12-31 |
$15.88B |
$11.95B |
75.24% |
| 2014-09-30 |
$16.06B |
$11.82B |
73.61% |
| 2014-06-30 |
$16.21B |
$11.80B |
72.81% |
| 2014-03-31 |
$16.37B |
$11.84B |
72.36% |
| 2013-12-31 |
$16.39B |
$11.77B |
71.81% |
| 2013-09-30 |
$16.14B |
$11.71B |
72.60% |
| 2013-06-30 |
$15.81B |
$11.57B |
73.22% |
| 2013-03-31 |
$16.20B |
$11.83B |
73.03% |
| 2012-12-31 |
$17.62B |
$13.01B |
73.84% |
| 2012-09-30 |
$18.88B |
$13.98B |
74.04% |
| 2012-06-30 |
$20.49B |
$15.17B |
74.03% |
| 2012-03-31 |
$21.48B |
$15.93B |
74.13% |
| 2011-12-31 |
$21.24B |
$15.65B |
73.65% |
| 2011-09-30 |
$20.90B |
$15.26B |
72.99% |
| 2011-06-30 |
$20.35B |
$14.84B |
72.89% |
| 2011-03-31 |
$19.69B |
$14.37B |
73.01% |
| 2010-12-31 |
$19.48B |
$14.21B |
72.92% |
| 2010-09-30 |
$19.41B |
$14.11B |
72.71% |
| 2010-06-30 |
$19.40B |
$14.06B |
72.50% |
| 2010-03-31 |
$19.29B |
$14.01B |
72.63% |
| 2009-12-31 |
$18.81B |
$13.67B |
72.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$163.981B |
$46.385B |
|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in New York.
|
